P
ancreatic adenocarcinoma recurrence after surgery (PARaS) is associated with poor outcomes. PARaS is locoregional in 50%-80%, effecting the resection bed and adjacent lymphatics. [1] [2] [3] Detection of PARaS via endoscopic ultrasound (EUS) is challenging because recurrent malignancy is difficult to distinguish from normal postoperative changes. Diagnosing PARaS is important, because salvage chemotherapy/radiation improves survival. 4, 5 The purpose of this investigation is to determine the clinical utility of EUS fine-needle aspiration (FNA) in patients with suspected PARaS.
Methods
A prospectively maintained database identified patients who underwent EUS for suspected local PARaS. Patients with distant metastases were excluded. Medical records were reviewed to obtain information regarding procedural indications, results of cross-sectional imaging before EUS, surgery performed, outcome of surgery, EUS results, clinical outcomes, laboratory, and pathology.
Patients were divided classified based on their imaging findings: group 1 consisted of patients with discrete masses on imaging, and group 2 of patients with nonspecific soft tissue thickening/lymphadenopathy.
The diagnosis of PARaS was made from positive cytology results coupled with laboratory (rising CA 19-9) and radiologic evidence of progressive disease. When cytology was negative, PARaS was based on laboratory and radiologic evidence of progressive disease.
Results
Of the 698 patients with surgical resection for pancreatic adenocarcinoma, 28 (4%) developed findings suspicious for local recurrence at a median of 20.7 (range, 9-42) months and were referred for EUS. Imaging findings at the time of suspected recurrence were mass lesion in the surgical bed in 12 (43%, group 1) and soft tissue thickening/lymphadenopathy in 16 (57%, group 2). A representative sampling of EUS and cross sectional images for patients in group 1 and 2 are illustrated in Figure 1 . FNA was performed in 19 (11/12 in group 1 and 8/16 in group 2; P ¼ .0003). Of the 12 patients in group 1, EUS identified a mass in 10. Of the 16 patients in group 2, none had discrete masses identified by EUS. Four patients demonstrated soft tissue thickening (3 on celiac artery, 1 surgical bed), 2 lymphadenopathy, and 1 an ill-defined region near the superior mesenteric artery. The remaining 9 (50%) patients in group 2 had no abnormalities on EUS that corresponded to those on imaging.
Among the 19 patients who underwent EUS-FNA (11 in group 1 and 8 in group 2), cytology was consistent with PARaS in 12 (10 in group 1 and 2 in group 2; P < .001). Seven patients (1 in group 1 and 6 in group 2) not diagnosed on EUS were subsequently diagnosed with PARaS during median follow-up of 6.4 (range, 0.5-56) months. Five of those patients had FNA performed, whereas the remaining 2 patients had no abnormalities on EUS. The overall sensitivity, specificity, and accuracy of EUS-FNA was 57%, 75%, and 68% respectively. EUS AE FNA had a significantly higher sensitivity (91% vs 22%; P ¼ .01) and accuracy (92% vs 56%; P < .001) in group 1, where a discrete mass was visualized on imaging, compared with group 2.
Discussion
Given high rates of PARaS and better survival of patients with local recurrence, early recognition of recurrence is paramount. Detecting PARaS via EUS is challenging because of anatomic alterations that decrease echoendoscope mobility and make it difficult to fully visualize the surgical bed, and nonspecific imaging findings that may represent postsurgical changes versus cancer recurrence.
In the only other study detailing the utility of EUS-FNA for PARaS, DeWitt et al 6 found a mass on EUS in 16/17 (94%) and FNA revealed malignancy in 13/16 (79%) patients. The sensitivity, specificity, and accuracy of EUS-FNA were 81%-93%, 100%, and 81%-93%, respectively. On the surface, our study shows different results regarding the sensitivity and accuracy of EUS for suspected PARaS depending on the pre-EUS imaging findings. Yet, after patients were separated based on imaging findings, the accuracy and sensitivity for those with a discrete mass on imaging (91% and 92%, respectively) was equal to that of DeWitt et al. 6 However, the sensitivity and accuracy for patients without a discrete mass were low, 22% and 56%, respectively.
EUS-FNA is a sensitive method for evaluating PARaS in patients with discrete mass lesions on imaging during postoperative surveillance. However, the yield of EUS in patients with imaging findings limited to soft tissue thickening and lymphadenopathy in or adjacent to the surgical bed is limited. These patients may be best served by close clinical and imaging follow-up rather than undergoing EUS-FNA, which affords a low sensitivity and accuracy in patients with nonspecific imaging findings. 
